Using high-resolution isoelectric focusing gel electrophoresis (IEF), two tamoxifen binding sites (TBS) with isoelectric point (pI) values of 4.5 and 4.3 were identified, with different affinities for tamoxifen. The form at pI 4.3 (HTBS) displayed high affinity for the ligand (kD approximately 5 nM), while the protein at pI 4.5 (LTBS) had lower affinity (kD approximately 50 nM). LTBS was found in the microsomal fraction and HTBS in the cytosol. Of a total of 319 tumours studied, 257 were oestrogen receptor (ER) positive and 106 HTBS positive. In this combined group, thus able to bind tamoxifen either through the presence of ER or HTBS (or both), ER and PR were both negatively correlated with HTBS (P < 0.0001). The oestrogen-induced protein ...
The DNA-binding sites of estrogen receptor α (ERα) show great plasticity under the control of hormon...
It is well-known that a majority of breast cancers are hormone-dependent, making endocrine therapy a...
Tamoxifen remains a frontline treatment for hormone-responsive breast cancer despite its use being a...
Steroid receptors and tamoxifen binding sites (TBS) were assayed in the soluble fraction of 121 prim...
Oestrogen receptors (ERs) in breast tumours are highly heterogeneous. In previous studies we have sh...
Using high resolution isoelectric focusing we have been able to identify a low affinity/high capacit...
The variability in the profile of oestrogen receptor (ER) isoforms in breast tumours has been studie...
Hormone dependency of mammary tumor was studied from the concentration of estrogen binding protein (...
The DNA-binding sites of estrogen receptor alpha (ER alpha) show great plasticity under the control ...
Anti-estrogen therapies like tamoxifen are the most successful breast cancer treatments to date. How...
In the United States in 2009, 192,370 women are expected to be diagnosed with invasive breast cancer...
Data were obtained on soluble oestrogen (ER) and progesterone (PR) receptors from 273 primary breast...
The proteins in an MCF-7 cell line were probed for tamoxifen (TAM) and <i>n</i>-desmethyl tamoxifen ...
The use of different techniques for assay of oestrogen receptors (ER) in breast cancer raises the qu...
Tamoxifen is an effective anti-estrogen for treatment of women with hormonedependent breast cancer b...
The DNA-binding sites of estrogen receptor α (ERα) show great plasticity under the control of hormon...
It is well-known that a majority of breast cancers are hormone-dependent, making endocrine therapy a...
Tamoxifen remains a frontline treatment for hormone-responsive breast cancer despite its use being a...
Steroid receptors and tamoxifen binding sites (TBS) were assayed in the soluble fraction of 121 prim...
Oestrogen receptors (ERs) in breast tumours are highly heterogeneous. In previous studies we have sh...
Using high resolution isoelectric focusing we have been able to identify a low affinity/high capacit...
The variability in the profile of oestrogen receptor (ER) isoforms in breast tumours has been studie...
Hormone dependency of mammary tumor was studied from the concentration of estrogen binding protein (...
The DNA-binding sites of estrogen receptor alpha (ER alpha) show great plasticity under the control ...
Anti-estrogen therapies like tamoxifen are the most successful breast cancer treatments to date. How...
In the United States in 2009, 192,370 women are expected to be diagnosed with invasive breast cancer...
Data were obtained on soluble oestrogen (ER) and progesterone (PR) receptors from 273 primary breast...
The proteins in an MCF-7 cell line were probed for tamoxifen (TAM) and <i>n</i>-desmethyl tamoxifen ...
The use of different techniques for assay of oestrogen receptors (ER) in breast cancer raises the qu...
Tamoxifen is an effective anti-estrogen for treatment of women with hormonedependent breast cancer b...
The DNA-binding sites of estrogen receptor α (ERα) show great plasticity under the control of hormon...
It is well-known that a majority of breast cancers are hormone-dependent, making endocrine therapy a...
Tamoxifen remains a frontline treatment for hormone-responsive breast cancer despite its use being a...